BCR and Miyoshi myopathy: Of special note, whereas nM concentrations of IBR are effective against B-cell lymphoma cancer cells, much higher μM concentrations seem to be required to kill BTK overexpressing MM cells [17,80,81,82,83], presumably because of the presence of highly redundant BCR/NFKB survival pathways (PI3K/Akt/mTOR/Syk) in MM, which compensates for pharmacological BTK inhibition [37].